For instance, the variation of prostate cancer incidence in France, as in many other countries, is mainly associated with changes in individual screening practices commencing with prostate-specific antigen measurement followed by a biopsy.22 A major increase was followed by a rapid decline in incidence between 2005 and 2020. The gene discussed is KLK3; the disease is prostate carcinoma.